Clinical trial
Phase IIa Trial of PD-L1 Peptide Vaccination as Monotherapy in High Risk Smoldering Multiple Myeloma
NCT03850522 is registered in ClinicalTrials.gov with Lene Meldgaard Knudsen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IIa Trial of PD-L1 Peptide Vaccination as Monotherapy in High Risk Smoldering Multiple Myeloma
- Lead sponsor
- Lene Meldgaard Knudsen
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 18, 2019
- Completion date
- March 10, 2021
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.